Dr. Liru He 何立儒
Chief Physician, Associate Professor
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy for urinary system tumors, focusing on prostate cancer, kidney cancer, and urothelial carcinoma. Expertise in image-guided intensity-modulated radiation therapy and stereotactic body radiation therapy.
Dr. He is a Chief Physician, Associate Professor, and doctoral supervisor. Dr. He was a visiting scholar at the University of Texas MD Anderson Cancer Center. Dr. He serves as an attending professor for urinary tumor radiation therapy at Sun Yat-sen University Cancer Center.
Professional roles
- Standing Committee Member, Urothelial Carcinoma Professional Committee, Chinese Society of Clinical Oncology (CSCO)
- Committee Member, Prostate Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Youth Committee Member, Urinary and Reproductive Tumor Professional Committee, China Anti-Cancer Association
- Vice Chair, Youth Committee of Urinary and Genital Tumor Specialty, Guangdong Anti-Cancer Association
Name order: in Chinese the family name comes first (He Liru). Papers usually list the name as Liru He or He L.
Selected publications
47 papers on PubMed matched by name and affiliation; 19 as first or senior author since 2016. Most recent first- or senior-author papers:
- Radiother Oncol, 2026 (senior author): Corrigendum to "Response evaluation and tumor shrinkage pattern post-SBRT for renal cell carcinoma" [Radiother. Oncol. 206 (2025) 110802]. PubMed 41956019
- Cell Rep Med, 2026 (senior author): Stereotactic body radiotherapy plus sunitinib vs. sunitinib alone in treatment-naive oligometastatic renal cell carcinoma: A phase 2 clinical trial. PubMed 42013852
- Bioengineering (Basel), 2025 (senior author): Auto-Segmentation and Auto-Planning in Automated Radiotherapy for Prostate Cancer. PubMed 40564436
- Radiother Oncol, 2025 (senior author): Response evaluation and tumor shrinkage pattern post-SBRT for renal cell carcinoma. PubMed 39993601
- Transl Androl Urol, 2025 (senior author): Clinical characteristics and prognostic factors of low metastatic burden prostate cancer with non-regional lymph node metastases: role of cytoreductive radiotherapy?. PubMed 40114834
- Ther Adv Med Oncol, 2023 (senior author): CXCL14 as a potential marker for immunotherapy response prediction in renal cell carcinoma. PubMed 38152696
- Cancer Med, 2022 (senior author): Locoregional recurrence after nephrectomy for localized renal cell carcinoma: Feasibility and outcomes of different treatment modalities. PubMed 35506551
- Clin Cancer Res, 2022 (senior author): Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. PubMed 36074152
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion